Topotecan Hospira
What Topotecan Hospira is used for
Topotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.
Approved use, as published by the European Medicines Agency.
Key facts
- Brand
- Topotecan Hospira
- Active substance
- topotecan
- Disease area
- Uterine Cervical Neoplasms; Small Cell Lung Carcinoma
- Medicine group
- Other antineoplastic agents
- ATC code
- L01CE01
- Marketing authorisation holder
- Pfizer Europe MA EEIG
- Authorised in the EU since
- 2010
Official information
In the USA
Same active substance: Hycamtin
In India
- Topotecan: 4 brands in India
Specialist medicine: started and supervised by a specialist doctor or hospital. This page is a plain-language summary of public official information, not medical advice; follow your doctor and the official product information.
Common questions
What is Topotecan Hospira used for?
Topotecan monotherapy is indicated for the treatment of patients with relapsed small-cell lung cancer (SCLC) for whom re-treatment with the first-line regimen is not considered appropriate. Topotecan in combination with cisplatin is indicated for patients with carcinoma of the cervix recurrent after radiotherapy and for patients with stage IVB disease. Patients with prior exposure to cisplatin require a sustained treatment-free interval to justify treatment with the combination.
What is the active substance in Topotecan Hospira?
Topotecan Hospira contains topotecan.
Who makes Topotecan Hospira?
The EU marketing authorisation holder is Pfizer Europe MA EEIG.
Source: European Medicines Agency medicines data (ema.europa.eu), reproduced with acknowledgement of the source. Page made 5 November 2026 by Satya Babu.
← All specialty medicines, EU